Form 4: Procept BioRobotics Executive Alaleh Nouri Reports Stock Transactions

Alaleh Nouri, EVP, CLO, and Corporate Secretary of Procept BioRobotics, reports acquisition and disposal of company stock and stock options.

Summary

• On March 3, 2025, Alaleh Nouri, EVP, CLO, CORP. SEC. of Procept BioRobotics Corp [PRCT], reported transactions involving the company's securities.
• Nouri acquired 12,958 shares of Common Stock in the form of Restricted Stock Units (RSUs) at $0.
• Nouri disposed of 65,430 shares of Common Stock.
• Nouri also acquired stock options (Right to Buy) for 11,445 shares at an exercise price of $60.6.
• Following these transactions, Nouri directly owns 11,445 derivative securities.
• The RSUs vest over time, with one-quarter vesting on March 5, 2026, and the remainder vesting quarterly over 36 months, contingent upon continued service.
• The stock options vest monthly from March 5, 2025, over a four-year period, subject to continued employment.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing. The acquisition of shares and options is mildly positive, while the disposal of shares is mildly negative. Overall, it balances out to a neutral sentiment.

Positives

• The acquisition of RSUs and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 65,430 shares by the executive could be interpreted negatively, although the reason for the disposal is not specified.

Risks

• The vesting of RSUs and stock options is contingent upon continued service/employment, creating a risk of forfeiture if the executive leaves the company.
• The value of the stock options is dependent on the future stock price, which is subject to market fluctuations.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a long-term commitment from the executive.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's common for executives to receive stock options and RSUs as part of their compensation packages.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech and medical device industries.
• Vesting schedules are typically structured to incentivize long-term employment and align executive interests with shareholder value.
• Companies like Intuitive Surgical and Stryker also utilize stock-based compensation for their executives.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how investors interpret the executive's actions.
• The vesting schedules incentivize the executive to remain with the company, which benefits employees and other stakeholders.

Key Dates